Stock 301047 SINO BIOLOGICAL,INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sino Biological,Inc.

Equities

301047

CNE100004Q23

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 27/06/2024 BST 		5-day change 1st Jan Change
59.95 CNY -0.30% Intraday chart for Sino Biological,Inc. -0.05% -27.25%
06-05 InDevR, Inc. and Sino Biological,Inc. Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy CI
05-15 Sino Biological,Inc. Approves Cash Dividend for the Year 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 23,508 12,876 10,646 7,659 - -
Enterprise Value (EV) 1 23,508 12,876 10,646 7,659 7,659 7,659
P/E ratio 27.2 x 37.4 x 40.9 x 29.5 x 24.1 x 25.7 x
Yield 2.89% 2.01% 2.43% - - -
Capitalization / Revenue 24.4 x 22.4 x 16.5 x 12.2 x 10.4 x 8.72 x
EV / Revenue 24.4 x 22.4 x 16.5 x 12.2 x 10.4 x 8.72 x
EV / EBITDA 27.2 x 35.7 x 31 x 25.7 x 21.6 x 18 x
EV / FCF 39,527,345 x - - - - -
FCF Yield 0% - - - - -
Price to Book 3.48 x 2.02 x 1.67 x 1.23 x 1.21 x 1.19 x
Nbr of stocks (in thousands) 129,200 129,200 129,200 127,760 - -
Reference price 2 181.9 99.66 82.40 59.95 59.95 59.95
Announcement Date 27/02/22 21/04/23 23/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 965.3 574.6 646.4 626 736 878
EBITDA 1 864.2 360.7 342.9 298 354 426
EBIT 1 841.7 342.5 287.9 235 280 342
Operating Margin 87.2% 59.61% 44.55% 37.54% 38.04% 38.95%
Earnings before Tax (EBT) 1 845.5 342.5 287.9 234 279 341
Net income 1 720 303.1 260.1 263.5 321.9 300
Net margin 74.59% 52.76% 40.24% 42.09% 43.74% 34.17%
EPS 2 6.687 2.661 2.013 2.035 2.490 2.330
Free Cash Flow 594.7 - - - - -
FCF margin 61.61% - - - - -
FCF Conversion (EBITDA) 68.82% - - - - -
FCF Conversion (Net income) 82.6% - - - - -
Dividend per Share 5.263 2.000 2.000 - - -
Announcement Date 27/02/22 21/04/23 23/04/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 595 - - - - -
ROE (net income / shareholders' equity) 18.8% 4.74% 4.11% 4.08% 4.78% 4.6%
ROA (Net income/ Total Assets) - - 3.95% 3.1% 3.7% 4.4%
Assets 1 - - 6,590 8,499 8,700 6,818
Book Value Per Share 2 52.30 49.30 49.30 48.90 49.50 50.30
Cash Flow per Share 5.970 1.930 2.500 - - -
Capex 1 47.9 156 1,043 108 90 63
Capex / Sales 4.96% 27.16% 161.41% 17.25% 12.23% 7.18%
Announcement Date 27/02/22 21/04/23 23/04/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Sino Biological,Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
59.95 CNY
Average target price
96 CNY
Spread / Average Target
+60.13%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SINO BIOLOGICAL,INC. Stock Sino Biological,Inc.
-27.25% 1.05B
MODERNA, INC. Stock Moderna, Inc.
+19.41% 45.51B
LONZA GROUP AG Stock Lonza Group AG
+38.65% 39.36B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.29B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 301047 Stock
  4. Financials Sino Biological,Inc.